title: In vivo gene therapy of murine melanoma mediated by recombinant vaccinia virus encoding human IL-2 gene.
abstract: Direct gene transfer into somatic tissue iii vivo is a developing technology with potential application for cancer gene therapy. In this study, recombinant vaccinia virus encoding human IL-2 gene (rVV-IL-2) was used as a candidate vector in mediating iii vivo gene therapy. After rVV-IL-2 was expanded in VERO cells for 72 h, high titer (10(8)-10(10) PFU/ml) rVV-IL-2 were harvested. When 10(6) murine melanoma cells (F16-F10) were infected with rVV-IL-2, about 200 U/ml IL-2 activity was detected in the supernatants at 8 h, and the up-regulation of ICAM-1 and MHC-I expressions on the melanoma cells were observed. The treatment of murine melanoma model by local injection of rVV-IL-2 into the tumor site showed that rVV-IL-2 transfection significantly inhibited the tumor growth and prolonged the survival time of tumor-bearing mice. The splenocytes from rVV-IL-2 treated mice showed higher cytotoxicities of NK, LAK and CTL in comparison with those from the controls. These results suggest that in vivo transfection mediated by rVV-IL-2 has potential effectiveness in enhancing host immunity and would be a useful approach to cancer gene therapy.
authors.affiliation: MIL MED COLL 2,DEPT IMMUNOL,SHANGHAI 200433,PEOPLES R CHINA. TRANSGENE SA,DEPT IMMUNOL,F-67082 STRASBOURG,FRANCE.
authors.forename: T
authors.initials: T
authors.lastname: Wan
authors.forename: X
authors.initials: X
authors.lastname: Cao
authors.forename: D
authors.initials: D
authors.lastname: Ju
authors.forename: B
authors.initials: B
authors.lastname: Aces